Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
關注Panbela Therapeutics;Roth MKM說:“'益普生食品藥品管理局批准Onivyde用於胰腺癌,而Panbela早些時候針對相同適應症的Sbp-101的1/1b期業績使投資者有理由感到樂觀。”重申買入和25美元的目標價”
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
關注Panbela Therapeutics;Roth MKM說:“'益普生食品藥品管理局批准Onivyde用於胰腺癌,而Panbela早些時候針對相同適應症的Sbp-101的1/1b期業績使投資者有理由感到樂觀。”重申買入和25美元的目標價”